Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
60%
Ph not_applicable
1
20%
Ph phase_2
1
20%

Phase Distribution

0

Early Stage

1

Mid Stage

3

Late Stage

Phase Distribution5 total trials
Phase 2Efficacy & side effects
1(20.0%)
Phase 3Large-scale testing
3(60.0%)
N/ANon-phased studies
1(20.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

5 of 5 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

5

all time

Status Distribution
Completed(5)

Detailed Status

Completed5

Development Timeline

Analytics

Development Status

Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 21 (20.0%)
Phase 33 (60.0%)
N/A1 (20.0%)

Trials by Status

completed5100%

Recent Activity

0 active trials
Showing 5 of 5
completednot_applicable

Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine

NCT05285384
completedphase_3

Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years

NCT05231590
completedphase_3

Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine

NCT05175625
completedphase_2

Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

NCT04944368
completedphase_3

Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

NCT05005559

Clinical Trials (5)

Showing 5 of 5 trials
NCT05285384Not Applicable

Immunogenicity and Safety of a Booster Dose of the SpikoGen Vaccine in Kidney Transplant Recipients After Two Doses of Sinopharm Vaccine

Completed
NCT05231590Phase 3

Immunogenicity and Safety of the SpikoGen COVID-19 Vaccine in Children Aged 5 to <12 Years and 12 to <18 Years Compared With Adults Aged 18 to 40 Years

Completed
NCT05175625Phase 3

Immunogenicity and Safety of a Booster Dose of the SpikoGen COVID-19 Vaccine

Completed
NCT04944368Phase 2

Phase II Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

Completed
NCT05005559Phase 3

Phase III Clinical Trial of CinnaGen COVID-19 Vaccine (SpikoGen)

Completed

All 5 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
5